UBS analyst Eliana Merle maintains $Apellis Pharmaceuticals (APLS.US)$ with a buy rating, and adjusts the target price from $83 to $45.
According to TipRanks data, the analyst has a success rate of 39.4% and a total average return of -5.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Apellis Pharmaceuticals (APLS.US)$'s main analysts recently are as follows:
Following the Q3 report, there's an identification of a distinct opportunity to develop a new thesis for 'post-GA' that is firmly rooted in the strong belief in the potential of C3G and IC-MPGN. The data for these are considered exceptionally robust and are viewed as superior to that of the oral competitor, especially in a wider context.
Following Apellis's report of Q3 Syfovre revenues that did not meet expectations, there remains anticipation for further insights into the geographic atrophy market's scope. Despite this, the valuation at present appears to underestimate the prospective market size, with the prospective introduction in C3G/IC-MPGN possibly mitigating the more gradual growth observed in the GA segment.
Apellis disclosed third-quarter results, which reflected a decrease in Syfovre revenue due to modest growth in vial numbers alongside a reduction in net pricing and heightened competition.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞士银行分析师Eliana Merle维持$Apellis Pharmaceuticals (APLS.US)$买入评级，并将目标价从83美元下调至45美元。
根据TipRanks数据显示，该分析师近一年总胜率为39.4%，总平均回报率为-5.4%。
此外，综合报道，$Apellis Pharmaceuticals (APLS.US)$近期主要分析师观点如下：
继第三季度报告之后，人们发现了一个难得的机会，可以为 “后GA” 提出新论点，该论点坚定地植根于对C3G和IC-MPGN潜力的坚定信念。这些数据被认为异常可靠，被认为优于口头竞争对手的数据，尤其是在更广泛的背景下。
继Apelis报告第三季度Syfovre收入未达到预期之后，人们仍有望进一步了解地域萎缩市场的范围。尽管如此，目前的估值似乎低估了潜在的市场规模，预期引入C3G/IC-MPGN可能会缓解GA细分市场中更为缓慢的增长。
Apellis披露了第三季度业绩，这反映了Syfovre收入的减少，这是由于小瓶数量的温和增长以及净定价的下降和竞争的加剧。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
